Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
‘Push-pull’ recipe for neural wiring used in multiple brain regions
A versatile pair of proteins steers neurons toward their targets and helps establish the brain’s sensory maps, new studies suggest.
‘Push-pull’ recipe for neural wiring used in multiple brain regions
A versatile pair of proteins steers neurons toward their targets and helps establish the brain’s sensory maps, new studies suggest.
Reward-learning algorithm hardwired into dopamine circuit
The finding bolsters the canonical model of reward prediction error, which has come under scrutiny in recent years.
Reward-learning algorithm hardwired into dopamine circuit
The finding bolsters the canonical model of reward prediction error, which has come under scrutiny in recent years.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.